美股市场个股详情

ACRV Acrivon Therapeutics

添加自选

9.820
+0.310+3.26%

收盘价 04/23 16:00 (美东)

3.03亿总市值-3583市盈率TTM

Acrivon Therapeutics股票讨论区

登录发表评论

Jaguar8

04/17 11:22

$Acrivon Therapeutics(ACRV.US)$
NEWS
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matche...

JESSE JAMES8832

04/16 04:29

and another huge buy 3.5m

$Acrivon Therapeutics(ACRV.US)$

JESSE JAMES8832

04/15 22:36

wow big insider loading 2.5m

$Acrivon Therapeutics(ACRV.US)$

Jaguar8

04/10 20:06

$Acrivon Therapeutics(ACRV.US)$
NEWS
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
Acrivon Therapeutics, Inc. announced data from two posters presented at the AACR Annual Meeting. ACR-2316, a dual WEE1/PKMYT1 inhibitor, showed potent anticancer activity in preclin...

Stock Region

04/10 03:53

$130 Million Private Placement Financing Secured By Therapeutics Company For Cancer Treatment

Acrivon Therapeutics Secures $130 Million in Private Placement Financing: A Leap Forward in Cancer Treatment Innovation.
In an era where the battle against cancer continues to demand innovative solutions, Acrivon Therapeutics has taken a significant step forward by securing $130 million through private placement financing. This move not only underscores the biotech industry's confidence in Acrivon's pote...